Institut Pasteur Korea – Hakim Djaballah, CEO
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
Institut Pasteur Korea is conceptualized around the virtual “genome to drugs” pipeline. The goal of IP-Korea is to actively implement post-genomic approaches into accelerated drug discovery. Accordingly, IP-Korea is situated at the very fault line between basic research and application.
The positioning of our institute is in good accordance with the Pasteurian tradition and mission. During its long history Institut Pasteur in Paris has been able to combine scientific achievements with their application in public health. This has improved the lives of millions of patients over the last 130 years, and has earned Institut Pasteur 10 Nobel prizes.
To extend and build on these achievements, IP-Korea is the first to develop a technology-based approach to therapeutic development in the areas of infectious and chronic diseases.
Strategically it combines its strength in biomedical research with Korean expertise in Information and Chemical technologies.
The result is the consequent implementation of visualization and imaging technology in analyzing disease models, accelerating both drug discovery and basic research.
Contact details
Address: 16, Daewangpangyo-ro 712beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
Tel: +82 31 8018 8000
Fax: +82 31 8018 8010
Email: ipkorea@ip-korea.org
www.ip-korea.org
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone…
Could you please introduce KPMA and explain the role it plays within the South Korean pharmaceutical industry? KPMA is the only association in South Korea regrouping the whole range of…
LG Life Sciences seems quite unique among the rest of pharmaceutical companies in Korea which tend to be family owned. How has this set LGLS apart in terms of its…
Could you introduce Lee & Ko to our readers? Established in 1977, Lee & Ko is the largest and the leading law firm in Korea, consisting of 310 professionals, including…
South Korea has a short history of participating in global clinical trials, but now the country is seeing exponential growth in this area. What has changed in recent years leading…
What are the main milestones and achievements of Daewoong’s pharmaceutical business over its decades of evolution? Daewoong was first established in 1945 as Chosun Liver-oil Pharmaceutical Industry Co., Ltd. The…
Could you provide our international readers with a profile of Bioneer as it stands today? Bioneer, having a strong basis of technology and experiences in molecular biology since 1992, we…
Although Chungcheongbuk-do is a small province in terms of territory and population, it has gained increasing importance in Korea’s economy. What are the main drivers of this growing economic progression?…
How did you first get involved in clinical trials and what inspired you to create your own CRO, ADM Korea? When I was working at CJ, the company was starting…
Novartis’ Head Office in Basel, Switzerland as well as several prior international assignments in Asia and Europe. What do you find as the most interesting particularities of the pharmaceutical sector…
Please introduce the Korean Food and Drug Administration (KFDA) and its main health-related responsibilities within the Korean government… The KFDA’s main duty is to cooperate and support with domestic and…
How would you rate South Korea’s healthcare system when compared to regional peers and other OECD countries – main strong points and room for improvement? Since the introduction of the…
See our Cookie Privacy Policy Here
